Development in Antimicrobial Resistance
Online Training Id: PPD-003
Geographical Region: Global
Duration: 2 hrs
To build upon the Personalised Medicine module, this course describes the methods and formulations used to target drug delivery. This includes targeting organs, such as the brain, and disease states, for example cancer.
Who Should Enroll:
All Research based Pharmaceutical Scientist
Claire is a Co-founder and Director at NanoScientium. Prior to this she was Head of Research and Development with Oxford Pharmascience, an AIM-listed Pharma company identified as one of the "Top 10 Emerging Technology Companies 2012". Oxford Pharmascience develops cutting edge technologies to enable medicines to be safer and easier to take. Prior to this, Claire spent 7½ years in Contract Research Organisations and large Pharma (Pfizer and GSK) developing novel molecules and formulations for therapeutic areas such as asthma, cancer, HIV, insomnia, malaria and pain. She attained increasingly senior roles leading global technical teams across R&D and manufacturing to deliver projects to milestones throughout the development lifecycle.
Claire was appointed Chief Scientist of the Academy of Pharmaceutical Sciences in June 2012 and has been a Board Member of the organisation since 2008. Claire holds a PhD from School of Pharmacy, University of Nottingham, and a BSc in Biochemistry from University of St. Andrews.
Dr Claire Thompson
CO-FOUNDER AND DIRECTOR AT NANOSCIENTIUM